louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01343212: Stiffness Measurement of Liver Tumors and Visceral Parenchyma
Official title: Clinical Applications of Acoustic Radiation Force Impulse Technology in Stiffness Measurement of Liver Tumors and Visceral Parenchyma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatocellular Carcinoma
Keywords: hepatocellular carcinoma
stiffness
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2011-04-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: subjects with hepatocellular carcinoma(HCC)

Brief summary: The investigators are measuring hepatocellular carcinoma(HCC)stiffness using Acoustic Radiation Force Impulse (ARFI) technique to enhance the diagnostic accuracy for HCC stratifications and treatment efficacy.

Detailed description: Regression modelings as well as validity testings including cut-off identification will be acquired by performing both qualitative and quantitative measurements of HCC using reference diagnostic modalities e.g. pathology grading, dynamic CT scanning, etc.

Eligibility criteria: Inclusion Criteria:

with HCC

Exclusion Criteria:

* subjects with liver cancer other than HCC
* subjects with treated HCC
* post major abdominal surgery
* contraindications to liver tumor biopsy
* contraindications to local percutaneous treatment of liver tumors
* ARFI measurement low quality

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital
Study officials:
affiliation: Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital
name: Sheng-Hung Chen, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital
name: Cheng-Yuan Peng, MD,PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01027312: Assessment of Ability Related to Vision
Official title: Reproducibility and Clinical Usefulness of AARV (Assessment of Ability Related to Vision)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma
Keywords: Glaucoma
quality of life
daily living activities
visual fields
contrast sensitivity
Lead sponsor: Wills Eye
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2009-12-07
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: One hundred patients with bilateral unstable glaucoma and twenty patients who appear to be normal will be enrolled.

Brief summary: To determine the clinical usefulness of a refined third-generation instrument - The Assessment of Ability Related to Vision (AARV) in establishing the amount of disability, charting the detrimental effects of progressive disease and establishing the beneficial effects of treatment

Detailed description: This research study is designed to test the usefulness and repeatability of testing how much disability is caused by vision loss due to glaucoma. We are recruiting 100 patients with glaucoma and 20 healthy (have no eye disease) individuals to be enrolled in this study. The healthy study participants will be enrolled in order to describe how a healthy individual will perform on the test designed to assess one's performance when completing ten activities of daily living.

Clinical testing will be conducted by binocular and monocular visual fields, contrast sensitivity and visual acuity. The NEI-VFQ 15 Quality of Life Questionnaire will be used to measure patients perception of how well they are doing.

Eligibility criteria: Inclusion Criteria:

* All patients 18 yrs of age and older
* must understand and respond to spoken English and be fully literate.

Exclusion Criteria:

* Patients with significant neurological problems (like Parkinson's disease), motor problems (like arthritis) or other significant illnesses that may prevent them from completing the testing involved in the study (like advanced heart failure).
* Patients who have received training related to low vision.

Primary outcomes:
measure: the reproducibility of AARV, and its relationship to standard clinical tests
timeFrame: Day 1, 1 week, 6 months, 1 year
Secondary outcomes:
measure: A better estimate of the reproducibility of standard clinical tests.
timeFrame: Day 1, 1 week, 6 months, 1 year
Other outcomes:
Locations:
Study officials:
affiliation: Wills Eye Institute
name: George L Spaeth, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wei H, Sawchyn AK, Myers JS, Katz LJ, Moster MR, Wizov SS, Steele M, Lo D, Spaeth GL. A clinical method to assess the effect of visual loss on the ability to perform activities of daily living. Br J Ophthalmol. 2012 May;96(5):735-41. doi: 10.1136/bjophthalmol-2011-300093. Epub 2012 Jan 12.
Clinical trial NCT04247412: Laryngomicrosurgery Under NIDP General Anesthesia Supported by THRIVE
Official title: Laryngomicrosurgery Under Nonintubated Deep Paralysis (NIDP) General Anesthesia Supported by Transnasal Humidified Rapid-insufflation Ventilatory Exchange: A Case Series Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vocal Polyp
Keywords: Laryngomicrosurgery
Nonintubated deep paralysis
Transnasal Humidified Rapid-insufflation Ventilatory Exchange
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2020-01-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young patients who will under elective polypectomy of unilateral vocal cord.

Brief summary: Laryngomicrosurgery requires deep paralysis and general anesthesia to finish the procedure. After the procedure, patients need a long time to recover. In the present study, with the support of the transnasal humidified rapid-insufflation ventilatory exchange, laryngomicrosurgery would be finished under nonintubated deep paralysis (NIDP) general anesthesia. In this case series study, the investigators will test the safety and feasibility of such a technique.


Eligibility criteria: Inclusion Criteria:

* elective polypectomy of unilateral vocal cord
* age between 18 to 40
* be able to communicate
* estimated operation time less than 15min
* ASA I-II
* Agree to sign written informed consent

Exclusion Criteria:

* pregnancy or breastfeeding women
* severe gastrointestinal reflex disease
* neuromuscular disease
* body mass index(BMI)\>30
* predictable difficult airway.
* allergy to medicine would be used in the present study including propofol, remifentanil or sugammadex

Primary outcomes:
measure: Success rate of laryngomicrosurgery
timeFrame: From the day before surgery till 2 days after surgery or before discharge
Secondary outcomes:
measure: Total days that participants stay in hospital
timeFrame: Through study completion, an average 2 days.
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT00038012: rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin
Official title: A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved With Thrombosol and 2% DMSO in Patients With Gynecologic Malignancy Receiving Carboplatin
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neoplasms, Gynecologic
Keywords: Dose-intensified carboplatin
autologous cryopreserved platelets
thrombopoietin
Gynecologic malignancy
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
Collaborators: name: Pharmacia
name: LifeCell
First posted: 2002-05-27
Enrollment: 33
Sex: FEMALE
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A Pilot Study of Transfusion of rhTPO-Derived Autologous Platelets Cryopreserved with ThromboSol and 2% DMSO in Patients with Gynecologic Malignancy Receiving Carboplatin


Eligibility criteria: INCLUSION CRITERIA:

* Patients with gynecologic malignancy for whom treatment with carboplatin is indicated.
* Age \>/= 15 years.
* Adequate hematologic, renal, and hepatic functions.
* Life expectancy \>/- 3 months. Karnofsky Performance Status \>/= 80.
* Signed informed consent form.

EXCLUSION CRITERIA:

* Patients with rapidly progressive disease.
* Pregnant or lactating women.
* Patients with comorbid condition which renders patients at high risk of treatment complication.
* History of CNS metastasis.
* Patients with significant cardiac disease (NYHA Class III or IV), dysrhythmia, or recent history of MI or ischemia, transient ischemic attack or CVA within the 6 months of study entry.
* Prior chemotherapy, immunotherapy, any experimental drug within 4 weeks, use of myeloid (G-CSF or GM-CSF) growth factors within 2 weeks or erythropoietin within 4 weeks.
* Use of any nitrosourea (BCNU, CCNU) or mitomycin - C within 6 weeks.
* Prior surgery or RT within 2 wks of study entry.
* Patients with history of prior high dose chemotherapy with stem cell transplant or with history of prolonged thrombocytopenia (\> 2 weeks).
* History of leukemia.
* History of any platelet disorders including ITP, TTP or bleeding disorders.
* History of \> 3 prior chemotherapy regimens (all platinum regimens will be counted as 1 regimen).
* Demonstrated lack of response to platinum-based therapy.

Primary outcomes:
measure: Response Rate
timeFrame: Continuous
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: UT MD Anderson Cancer Center
name: Saroj Vadhan-Raj, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06610812: "KETOGENIC MEDITERRANEAN VERSUS HYPOCALORIC BALANCED DIET ON POLYCYSTIC OVARIAN ADOLESCENTS"
Official title: KETOGENIC MEDITERRANEAN VERSUS HYPOCALORIC BALANCED DIET ON Added to Aerobic Exercises POLYCYSTIC OVARIAN ADOLESCENTS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Polycystic Ovary Disease
Lead sponsor: MTI University
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 40
Sex: FEMALE
Minimum age (years): 16
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trail
Primary purpose: TREATMENT

Brief summary: study was designed to determine the effect of ketogenic Mediterranean diet versus hypocaloric balanced diet on adolescent female with polycystic ovary disease.

Detailed description: this study wsa designed to investigate the effect of the ketogenic Mediterranean diet in comparison with hypo-caloric diet on obese adolescent female's patients with polycystic ovary disease trying to find out a new physical therapy approach that had positive effect in the treatment and care for such cases which could enhance the physical therapy field.

Eligibility criteria: Inclusion Criteria:

1 - All patients were adolescent females. 2- All patients ages ranged from 16 to 21years old. 3- Their BMI ranged from 25kg/m² to 35kg/m². 4- All patients were suffering from hormonal disturbances confirmed by their lab tests and cysts in the ovaries that confirm their diagnosis with polycystic ovary disease.

5- They were conscious and free from any other medical disease.

Exclusion Criteria:

Patients were examined by a gynecologist before the study and excluded if they have:

1. Cardiac problems, epileptics and implanted pacemakers.
2. Pregnancy.
3. Malignancy and cardiovascular disease.
4. Women with skin infection.
5. Dysesthesia.
6. Cerebrovascular disease.
7. Uncontrolled diabetes.
8. Severe uncontrolled cardiac patient.
9. Liver and kidney dysfunction.

Primary outcomes:
measure: LH/FSH
timeFrame: 3 months
measure: body mass index
timeFrame: 3 months
Secondary outcomes:
measure: waist-hip ratio
timeFrame: 3 months
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo Unversity
Study officials:
References:
Clinical trial NCT00963612: Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)
Official title: Non-Invasive Prediction of Microvascular Invasion (MVI) in Hepatocellular Carcinoma (HCC) by Assessment of Tumor Oxygenation by Blood Oxygen Level-Dependent Magnetic Resonance Imaging (BOLD MRI)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Keywords: Microvascular Invasion
Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2009-08-21
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Liver resection and liver transplantation are the acceptable treatment of Hepatocellular Carcinoma (HCC). But the long-term survival is unsatisfactory as a result of high rate of intra and extra hepatic recurrences. Microvascular invasion (MVI) is the most significant risk factor affecting recurrence-free survival in patients following liver resection and liver transplantation. Tumor hypoxia (lack of adequate blood supply) is the single most important factor that predict MVI and post surgical prognosis.

Blood Oxygen Level Dependent (BOLD) MRI is a non-invasive diagnostic method of assessing tumor hypoxia by detecting signal changes secondary to changes in blood flow and oxygenation. BOLD MRI assessment of tumor hypoxia in HCC has never been correlated with pathological confirmation of MVI, the gold standard to assess MVI in HCC. In this study, the investigators propose to assess the ability of BOLD MRI to provide a discriminating quantitative threshold of intratumoral oxygenation predictive of MVI.


Eligibility criteria: Inclusion Criteria:

* Patients with known Hepatocellular Carcinoma;
* Scheduled to undergo liver resection or liver transplantation.

Exclusion Criteria:

* Estimated GFR (eGFR \< 30 mL/min;
* MRI contrast allergy;
* General contraindications to MRI such as pacemaker, etc.;
* Prior tumor treatment such as transarterial chemoembolization or the tumor or radiofrequency ablation or chemoradiation;
* Pregnancy;
* Age less than 18 years.

Primary outcomes:
measure: To assess the ability of BOLD MRI to predict microvascular invasion in hepatocellular carcinoma via assessment of intratumoral oxygenation.
timeFrame: 18 months
Secondary outcomes:
measure: To identify a quantitative threshold tumor R2* value using BOLD MRI technique reasonably sensitive of predicting microvascular invasion in HCC pre-operatively.
timeFrame: 18 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Kartik Jhaveri, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06383312: Magnetic Reflexologic Insoles for Primary Dysmenorrhea
Official title: Investigation of the Effectiveness of Reflexologic Magnetic Insoles on Dysmenorrhea Symptoms in Primary Dysmenorrhea
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Primary Dysmenorrhea
Keywords: Dysmenorrhea
Reflexology
Pain
Foot Orthoses
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two groups; treatment group and sham group
Primary purpose: TREATMENT

Brief summary: In the study, easy-to-access and easy-to-use reflexologic magnetic insoles were used in women with primary dysmenorrhea who did not want to receive medical treatment; In addition to reducing symptoms such as pain, nausea, dizziness, fainting, vomiting, weakness, constipation/acute gastroenteritis, it is aimed to increase individuals' participation in daily life activities and increase their quality of life by increasing their emotional state.

Detailed description: 60 women diagnosed with primary dysmenorrhea through examination by a gynecologist will be included in the study. 60 women will be randomly divided into 2 groups. These groups; Reflexologic Magnetic Insoles Sham Group: They will use orthopedic insoles.

Eligibility criteria: Inclusion Criteria:

* Having been diagnosed with primary dysmenorrhea
* Visual Analogue Scale (VAS) value is 3 and above
* The patient has cooperation
* Having regular menstruation

Exclusion Criteria:

* Getting pregnant during treatment
* Using analgesic medication
* Visual Analogue Scale (VAS) value should be between 0-3
* Having pain in another part of the body

Primary outcomes:
measure: McGill Pain Questionnaire-Short Form:
timeFrame: 12 weeks
measure: Menstruation Attitude Questionnaire
timeFrame: 12 weeks
measure: Menstruation Symptom Questionnaire
timeFrame: 12 weeks
measure: Visual Analogue Scale (VAS)
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
Study officials:
affiliation: Medipol University
name: Gizem BOZTAŞ ELVERİŞLİ, Ph.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT00539812: Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women
Official title: Brief Intervention to Reduce Drinking and Intimate Partner Violence in Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Intimate Partner Violence
Substance Use
Keywords: Intimate partner violence
alcohol use
substance use
Lead sponsor: The University of Tennessee, Knoxville
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
name: Butler Hospital
First posted: 2007-10-05
Enrollment: 225
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine whether adding a brief alcohol treatment to standard violence intervention programs for women will result in reduced drinking, reduced partner violence perpetration, and reduced partner violence victimization. We hypothesize that, relative to standard care, women receiving the additional brief alcohol intervention will have better alcohol use and partner violence outcomes.


Eligibility criteria: Inclusion Criteria:

* Hazardous drinking
* Participation in a batterer intervention program

Primary outcomes:
measure: Substance use and intimate partner violence
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: Butler Hospital & University of Tennessee-Knoxville
state: Rhode Island
Study officials:
affiliation: University of Tennessee-Knoxville & Butler Hospital
name: Gregory L Stuart, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03720912: Behavioral Family Therapy and Type One Diabetes
Official title: Effect of Behavioral Family Therapy on Glycemic Control in Children With Type One Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Lead sponsor: University of California, Davis
Sponsor class: OTHER
Collaborators: name: University of Nevada, Reno
First posted: 2018-10-25
Enrollment: 75
Sex: ALL
Minimum age (years): 2
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Behavioral family therapy, specifically focused on insuring support for the primary caregiver of a child with type one diabetes mellitus and healthy family dynamics, may improve the child's glycemic control as measured by hemoglobin A1c level (HbA1c).

Detailed description: The success or failure of type 1 diabetes mellitus (T1D) management in children depends not only on access to care, diabetes technologies and diabetes education, but also on the abilities of the patient and his/her family to carry out complex demands. Recent data show that family dynamics play a critical role in determining glycemic control in pediatric patients with T1D. The investigators prior work (Loomba-Albrecht and Glaser, unpublished data) suggests that the strongest determinants of glycemic control are factors related to the primary caregiver's involvement in supportive relationships with others, either a spouse or other family members. This provides a potential therapeutic target to improve outcomes for children with T1D.

Eligibility criteria: Inclusion Criteria:

* age 2 to 17 years
* newly diagnosed (within the past 12 weeks) with T1D
* seeking care at UC Davis

Exclusion Criteria:

- Families will be excluded if the child has severe underlying psychiatric, behavioral or medical conditions which could independently affect parental marital stress

Primary outcomes:
measure: Change in HbA1c Level
timeFrame: 6, 12, 18, and 24 months
Secondary outcomes:
measure: Behavioral Affect Rating
timeFrame: At enrollment and approximately 3 months after enrollment
measure: Child Perception of Interparental Conflict (CPIC)
timeFrame: At enrollment and approximately 3 months after enrollment
measure: Family Assessment Device-General Functioning Subscale
timeFrame: At enrollment and approximately 3 months after enrollment
measure: Patient-Reported Outcomes Information System- Short Forms (PROMIS)
timeFrame: At enrollment and approximately 3 months after enrollment
measure: FoH-C Frequency of Help
timeFrame: At enrollment and approximately 3 months after enrollment
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California-Davis
state: California
Study officials:
References: